Renal cell carcinoma

The Lancet

Volumn 373, Issue 9669, 2009, Pages 1119-1132

  Rini, Brian I ^a   Campbell, Steven C ^b   Escudier, Bernard ^c  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; BEVACIZUMAB; EVEROLIMUS; MEDROXYPROGESTERONE ACETATE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN INHIBITOR;

ANEMIA; ANOREXIA; ASTHENIA; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CYTOREDUCTIVE SURGERY; DYSPNEA; FATIGUE; HISTOPATHOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOTHERAPY; KIDNEY CARCINOMA; KIDNEY FUNCTION; METASTASIS; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RADIOFREQUENCY ABLATION; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 62849128369     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60229-4     Document Type: Review

References (135)

1. Gupta K., Miller J.D., Li J.Z., Russell M.W., and Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 34 (2008) 193-205
2. Chow W.H., Devesa S.S., Warren J.L., and Fraumeni Jr. J.F. Rising incidence of renal cell cancer in the United States. JAMA 281 (1999) 1628-1631
3. Hollingsworth J.M., Miller D.C., Daignault S., and Hollenbeck B.K. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 98 (2006) 1331-1334
4. Hollingsworth J.M., Miller D.C., Daignault S., and Hollenbeck B.K. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer 109 (2007) 1763-1768
5. Hunt J.D., van der Hel O.L., McMillan G.P., Boffetta P., and Brennan P. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer 114 (2005) 101-108
6. Yuan J.M., Castelao J.E., Gago-Dominguez M., Yu M.C., and Ross R.K. Tobacco use in relation to renal cell carcinoma. Cancer Epidemiol Biomarkers Prev 7 (1998) 429-433
7. Bjorge T., Tretli S., and Engeland A. Relation of height and body mass index to renal cell carcinoma in two million Norwegian men and women. Am J Epidemiol 160 (2004) 1168-1176
8. van Dijk B.A., Schouten L.J., Kiemeney L.A., Goldbohm R.A., and van den Brandt P.A. Relation of height, body mass, energy intake, and physical activity to risk of renal cell carcinoma: results from the Netherlands Cohort Study. Am J Epidemiol 160 (2004) 1159-1167
9. van Dijk B.A., Schouten L.J., Kiemeney L.A., Goldbohm R.A., and van den Brandt P.A. Vegetable and fruit consumption and risk of renal cell carcinoma: Results from the Netherlands cohort study. Int J Cancer 117 (2005) 648-654
10. Lee J.E., Hunter D.J., Spiegelman D., et al. Intakes of coffee, tea, milk, soda and juice and renal cell cancer in a pooled analysis of 13 prospective studies. Int J Cancer 121 (2007) 2246-2253
11. Rashidkhani B., Lindblad P., and Wolk A. Fruits, vegetables and risk of renal cell carcinoma: a prospective study of Swedish women. Int J Cancer 113 (2005) 451-455
12. McLaughlin J.K., Chow W.H., Mandel J.S., et al. International renal-cell cancer study. VIII. Role of diuretics, other anti-hypertensive medications and hypertension. Int J Cancer 63 (1995) 216-221
13. Ishikawa I., Saito Y., Asaka M., et al. Twenty-year follow-up of acquired renal cystic disease. Clin Nephrol 59 (2003) 153-159
14. Rakowski S.K., Winterkorn E.B., Paul E., Steele D.J., Halpern E.F., and Thiele E.A. Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors. Kidney Int 70 (2006) 1777-1782
15. McCredie M., Pommer W., McLaughlin J.K., et al. International renal-cell cancer study. II. Analgesics. Int J Cancer 60 (1995) 345-349
16. Linehan W.M., Walther M.M., and Zbar B. The genetic basis of cancer of the kidney. J Urol 170 (2003) 2163-2172
17. Lonser R.R., Glenn G.M., Walther M., et al. von Hippel-Lindau disease. Lancet 361 (2003) 2059-2067
18. Latif F., Tory K., Gnarra J., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260 (1993) 1317-1320
19. Walther M.M., Choyke P.L., Glenn G., et al. Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol 161 (1999) 1475-1479
20. Campbell S.C., Novick A.C., and Bukowski R.M. Renal tumors. In: Kavoussi L.R., Novick A.C., Partin A.W., et al. (Eds). Campbell's urology. 9th edn. (2007), Saunders Elsevier, Philadelphia
21. Prasad S.R., Surabhi V.R., Menias C.O., Raut A.A., and Chintapalli K.N. Benign renal neoplasms in adults: cross-sectional imaging findings. AJR Am J Roentgenol 190 (2008) 158-164
22. Chao D.H., Zisman A., Pantuck A.J., Freedland S.J., Said J.W., and Belldegrun A.S. Changing concepts in the management of renal oncocytoma. Urology 59 (2002) 635-642
23. Lane B.R., Samplaski M.K., Herts B.R., Zhou M., Novick A.C., and Campbell S.C. Renal mass biopsy-a renaissance?. J Urol 179 (2008) 20-27
24. Renshaw A.A. Subclassification of renal cell neoplasms: an update for the practising pathologist. Histopathology 41 (2002) 283-300
25. Storkel S., Eble J.N., Adlakha K., et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80 (1997) 987-989
26. Zambrano N.R., Lubensky I.A., Merino M.J., Linehan W.M., and Walther M.M. Histopathology and molecular genetics of renal tumors toward unification of a classification system. J Urol 162 (1999) 1246-1258
27. Fuhrman S.A., Lasky L.C., and Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6 (1982) 655-663
28. Davis Jr. C.J., Mostofi F.K., and Sesterhenn I.A. Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol 19 (1995) 1-11
29. Cheville J.C., Lohse C.M., Zincke H., et al. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 28 (2004) 435-441
30. Farrow G.M., Harrison Jr. E.G., and Utz D.C. Sarcomas and sarcomatoid and mixed malignant tumors of the kidney in adults. 3. Cancer 22 (1968) 556-563
31. Uzzo R., and Novick A.C. Nephron sparing surgery for renal tumors: indications, techniques and outcomes. J Urol 166 (2001) 6
32. Butler B.P., Novick A.C., Miller D.P., Campbell S.A., and Licht M.R. Management of small unilateral renal cell carcinomas: radical versus nephron-sparing surgery. Urology 45 (1995) 34-40 discussion 40-41.
33. Lerner S.E., Hawkins C.A., Blute M.L., et al. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J Urol 155 (1996) 1868-1873
34. Gill I.S., Kavoussi L.R., Lane B.R., Blute M.L., Babineau D., Colombo Jr. J.R., et al. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol 178 (2007) 41-46
35. Lane B.R., Novick A.C., Babineau D., Fergany A.F., Kaouk J.H., and Gill I.S. Comparison of laparoscopic and open partial nephrectomy for tumor in a solitary kidney. J Urol 179 (2008) 847-851 discussion 52.
36. Huang W.C., Levey A.S., Serio A.M., et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 7 (2006) 735-740
37. Fried L.F., Katz R., Sarnak M.J., et al. Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol 16 (2005) 3728-3735
38. Go A.S., Chertow G.M., Fan D., McCulloch C.E., and Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
39. Sarnak M.J., Levey A.S., Schoolwerth A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 42 (2003) 1050-1065
40. Gill I.S., Novick A.C., Meraney A.M., et al. Laparoscopic renal cryoablation in 32 patients. Urology 56 (2000) 748-753
41. Gill I.S., Remer E.M., Hasan W.A., et al. Renal cryoablation: outcome at 3 years. J Urol 173 (2005) 1903-1907
42. Hafron J., and Kaouk J.H. Ablative techniques for the management of kidney cancer. Nat Clin Pract 4 (2007) 261-269
43. Kunkle D.A., Egleston B.L., and Uzzo R.G. Excise, ablate or observe: the small renal mass dilemma-a meta-analysis and review. J Urol 179 (2008) 1227-1233
44. Weight C.J., Kaouk J.H., Hegarty N.J., et al. Correlation of radiographic imaging and histopathology following cryoablation and radio frequency ablation for renal tumors. J Urol 179 (2008) 1277-1281
45. Chawla S.N., Crispen P.L., Hanlon A.L., Greenberg R.E., Chen D.Y., and Uzzo R.G. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 175 (2006) 425-431
46. Frank I., Blute M.L., Cheville J.C., Lohse C.M., Weaver A.L., and Zincke H. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol 170 (2003) 2217-2220
47. Remzi M., Ozsoy M., Klingler H.C., et al. Are small renal tumors harmless? Analysis of histopathological features according to tumors 4 cm or less in diameter. J Urol 176 (2006) 896-899
48. Hollenbeck B.K., Taub D.A., Miller D.C., Dunn R.L., and Wei J.T. National utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization?. Urology 67 (2006) 254-259
49. Leibovich B.C., Blute M.L., Cheville J.C., Lohse C.M., Weaver A.L., and Zincke H. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 171 (2004) 1066-1070
50. Blute M.L., Leibovich B.C., Lohse C.M., Cheville J.C., and Zincke H. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int 94 (2004) 33-41
51. Margulis V., Sanchez-Ortiz R.F., Tamboli P., Cohen D.D., Swanson D.A., and Wood C.G. Renal cell carcinoma clinically involving adjacent organs: experience with aggressive surgical management. Cancer 109 (2007) 2025-2030
52. Kattan M.W., Reuter V., and Motzer R.J. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 166 (2001) 63-67
53. Leibovich B.C., Blute M.L., Cheville J.C., et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97 (2003) 1663-1671
54. Zisman A., Pantuck A.J., Dorey F., et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 19 (2001) 1649-1657
55. Galligioni E., Quaia M., Merlo A., et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer 77 (1996) 2560-2566
56. Messing E.M., Manola J., Wilding G., et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 21 (2003) 1214-1222
57. Pizzocaro G., Piva L., Colavita M., et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 19 (2001) 425-431
58. Clark J.I., Atkins M.B., Urba W.J., et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 21 (2003) 3133-3140
59. Atzpodien J., Schmitt E., Gertenbach U., et al. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 92 (2005) 843-846
60. Gez E., Libes M., Bar-Deroma R., Rubinov R., Stein M., and Kuten A. Postoperative irradiation in localized renal cell carcinoma: the Rambam Medical Center experience. Tumori 88 (2002) 500-502
61. Kjaer M., Frederiksen P.L., and Engelholm S.A. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys 13 (1987) 665-672
62. Makarewicz R., Zarzycka M., Kulinska G., and Windorbska W. The value of postoperative radiotherapy in advanced renal cell cancer. Neoplasma 45 (1998) 380-383
63. Pizzocaro G., Piva L., Di Fronzo G., et al. Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J Urol 138 (1987) 1379-1381
64. Flanigan R.C., Mickisch G., Sylvester R., Tangen C., Van Poppel H., and Crawford E.D. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171 (2004) 1071-1076
65. Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345 (2001) 1655-1659
66. Mickisch G.H., Garin A., van Poppel H., de Prijck L., and Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358 (2001) 966-970
67. Rini B.I., and Campbell S.C. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. J Urol 177 (2007) 1978-1984
68. Murthy S.C., Kim K., Rice T.W., et al. Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma?. Ann Thorac Surg 79 (2005) 996-1003
69. Pfannschmidt J., Hoffmann H., Muley T., Krysa S., Trainer C., and Dienemann H. Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 74 (2002) 1653-1657
70. Papac R.J., Ross S.A., and Levy A. Renal cell carcinoma: analysis of 31 cases with assessment of endocrine therapy. Am J Med Sci 274 (1977) 281-290
71. Pizzocaro G., Di Fronzo G., Cappelletti V., et al. Hormone treatment and sex steroid receptors in metastatic renal cell carcinoma: report of a multicentric prospective study. Tumori 69 (1983) 215-220
72. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 353 (1999) 14-17
73. Yagoda A., Abi-Rached B., and Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 22 (1995) 42-60
74. Motzer R.J., and Russo P. Systemic therapy for renal cell carcinoma. J Urol 163 (2000) 408-417
75. Rini B.I., Vogelzang N.J., Dumas M.C., Wade III J.L., Taber D.A., and Stadler W.M. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 18 (2000) 2419-2426
76. McDermott D.F., Regan M.M., Clark J.I., et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 133-141
77. Yang J.C., Sherry R.M., Steinberg S.M., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21 (2003) 3127-3132
78. Pyrhonen S., Salminen E., Ruutu M., et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17 (1999) 2859-2867
79. Coppin C., Porzsolt F., Awa A., Kumpf J., Coldman A., and Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 1 (2005) CD001425.
80. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
81. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
82. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
83. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
84. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
85. Szcylik C., Demkow T., Staehler M., et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results. J Clin Oncol 25 (2007) 5025
86. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 (2007) 2103-2111
87. Rini B.I., Halabi S.H., Rosenberg J.E., et al. Bevacizumab plus Interferon-alpha versus Interferon-alpha Monotherapy in Patients with Metastatic Renal Cell Carcinoma: results of CALGB 90206. J Clin Oncol 26 (2008) 5422-5428
88. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
89. Bukowski R.M., Kabbinavar F.F., Figlin R.A., et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 25 (2007) 4536-4541
90. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918
91. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
92. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Nat Cancer Inst 92 (2000) 205-216
93. Rini B.I., Weinberg V., and Small E.J. A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma. Cancer 103 (2005) 553-558
94. Stadler W.M., Halabi S., Rini B., et al. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer 107 (2006) 1273-1279
95. Fossa S.D., Droz J.P., Pavone-Macaluso M.M., Debruyne F.J., Vermeylen K., and Sylvester R. Vinblastine in metastatic renal cell carcinoma: EORTC phase II trial 30882. The EORTC Genitourinary Group. Eur J Cancer 28 (1992) 878-880
96. Neidhart J.A., Anderson S.A., Harris J.E., et al. Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases. J Clin Oncol 9 (1991) 832-836
97. Rosenberg S.A., Lotze M.T., Muul L.M., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313 (1985) 1485-1492
98. Fyfe G., Fisher R.I., Rosenberg S.A., Sznol M., Parkinson D.R., and Louie A.C. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13 (1995) 688-696
99. Fyfe G.A., Fisher R.I., Rosenberg S.A., Sznol M., Parkinson D.R., and Louie A.C. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 14 (1996) 2410-2411
100. Fisher R.I., Rosenberg S.A., and Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6 suppl 1 (2000) S55-S57
101. Atkins M., Regan M., McDermott D., et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11 (2005) 3714-3721
102. Bui M.H., Seligson D., Han K.R., et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9 (2003) 802-811
103. Upton M.P., Parker R.A., Youmans A., McDermott D.F., and Atkins M.B. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 28 (2005) 488-495
104. Negrier S., Escudier B., Lasset C., et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 338 (1998) 1272-1278
105. Escudier B., Chevreau C., Lasset C., et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Francais d'Immunotherape. J Clin Oncol 17 (1999) 2039-2043
106. Negrier S., Escudier B., Gomez F., et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann Oncol 13 (2002) 1460-1468
107. Negrier S., Perol D., Ravaud A., et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 110 (2007) 2468-2477
108. Atzpodien J., Kirchner H., Hanninen E.L., Deckert M., Fenner M., and Poliwoda H. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 29 suppl 5 (1993) S6-S8
109. Atzpodien J., Kirchner H., Illiger H.J., et al. IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 85 (2001) 1130-1136
110. Atzpodien J., and Kirchner H. J immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22 (2004) 1188-1194
111. Gore M.E. Interferon-α (IFN), interleukin-2 (IL2) and 5-fluorouracil (5FU) vs IFN alone in patients with metastatic renal cell carcinoma (mRCC): Results of the randomised MRC/EORTC RE04 trial. J Clin Oncol 26 suppl (2008) 5039 (abstr).
112. Clifford S.C., Prowse A.H., Affara N.A., Buys C.H., and Maher E.R. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 22 (1998) 200-209
113. Gnarra J.R., Tory K., Weng Y., et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7 (1994) 85-90
114. Gallou C., Joly D., Mejean A., et al. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum Mutat 13 (1999) 464-475
115. Schraml P., Struckmann K., Hatz F., et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 196 (2002) 186-193
116. Herman J.G., Latif F., Weng Y., et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91 (1994) 9700-9704
117. Gnarra J.R., Zhou S., Merrill M.J., et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 93 (1996) 10589-10594
118. Kourembanas S., Hannan R.L., and Faller D.V. Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells. J Clin Invest 86 (1990) 670-674
119. de Paulsen N., Brychzy A., Fournier M.C., et al. Role of transforming growth factor-alpha in von Hippel-Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci USA 98 (2001) 1387-1392
120. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
121. Figlin RA, Hutson TE, Tomczak P, et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). Program and abstracts of the 44th American Society of Clinical Oncology Annual Meeting; Chicago, IL, USA; May 30-June 3, 2008. Abstract 5024.
122. Rini B.I., Tamaskar I., Shaheen P., et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99 (2007) 81-83
123. Chu T.F., Rupnick M.A., Kerkela R., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370 (2007) 2011-2019
124. Khakoo A.Y., Kassiotis C.M., Tannir N., et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 112 (2008) 2500-2508
125. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
126. Bukowski R.M., Eisen T., Szczylik C., et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis. J Clin Oncol 25 18 suppl (2007) 5023 (abstr).
127. Escudier B., Szczylik C., Hutson T.E., et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alpha-2a in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 10.1200/JCO.2008.19.3342 published online Jan 26.
128. Presta L.G., Chen H., O'Connor S.J., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57 (1997) 4593-4599
129. Rini B.I. Temsirolimus, an inhibitor of Mammalian target of rapamycin. Clin Cancer Res 14 (2008) 1286-1290
130. Abraham R.T., and Gibbons J.J. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 13 (2007) 3109-3114
131. Sabatini D.M. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6 (2006) 729-734
132. Motzer R.J., Mazumdar M., Bacik J., Berg W., Amsterdam A., and Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 (1999) 2530-2540
133. Mekhail T.M., Abou-Jawde R.M., Boumerhi G., et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 832-841
134. Motzer R.J., Escudier B., Oudard S., et al., for the RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372 (2008) 449-456
135. Tamaskar I., Garcia J.A., Elson P., et al. Antitumor Effects of Sunitinib or Sorafenib in Patients With Metastatic Renal Cell Carcinoma Who Received Prior Antiangiogenic Therapy. J Urol 179 (2007) 81-86